Pinned straw:
Hi @raymon68
Im not sure that the potential reclassification of cannabinoids in the US should impact BXN directly - either positively or negatively. I suppose it might introduce more global competition eventually, but BXN doesn’t operate on the US.
The other bit of news is the change in government in Czechia. They may view medical cannabis unfavourably. The medium term ramp up of European supply is dependent on a new facility being built there but currently they have excess capacity in their Australian manufacturing plant for the next 12-24 months.
It’s possible that there has been a sell down from a significant shareholder over the last month or so but there has been no announcement to that effect
Hope that helps
c